Artemis Medicare Services Limited

rs,

Kurla Complex, Bandra (E), Mumbai – 400 051 The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 NSE Code: ARTEMISMED Scrip Code: 542919 Sub: Earnings Presenta

67%

d 9M FY2025 Artemis Hospitals : At a Glance Established in July 2007 by promoters of Apollo Tyres (67% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR 800+

rs 40

t centres operating cardiac care centres across India 500+ 500+ Full time Doctors Full time Doctors 40+ Specialities 12 Centres of Excellence 2 Consolidated Financial Highlights – Q3 FY25 Gross Re

6.3%

ialities 12 Centres of Excellence 2 Consolidated Financial Highlights – Q3 FY25 Gross Revenue 6.3% Key Financials (INR Mn) Net Revenue 6.7% 6.3% 2,287 2,431 6,865 7,298 6.2% 2,188 2,

6.7%

olidated Financial Highlights – Q3 FY25 Gross Revenue 6.3% Key Financials (INR Mn) Net Revenue 6.7% 6.3% 2,287 2,431 6,865 7,298 6.2% 2,188 2,324 6,533 6,970 EBITDA 36.3% 1,002

6.2%

ss Revenue 6.3% Key Financials (INR Mn) Net Revenue 6.7% 6.3% 2,287 2,431 6,865 7,298 6.2% 2,188 2,324 6,533 6,970 EBITDA 36.3% 1,002 1,365 34.4% 344 463 Q3 FY24 Q3 FY25

36.3%

Revenue 6.7% 6.3% 2,287 2,431 6,865 7,298 6.2% 2,188 2,324 6,533 6,970 EBITDA 36.3% 1,002 1,365 34.4% 344 463 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24

34.4%

,287 2,431 6,865 7,298 6.2% 2,188 2,324 6,533 6,970 EBITDA 36.3% 1,002 1,365 34.4% 344 463 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY

15.7%

9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Margin: 15.7% 19.9% 15.3% 19.6% Dr. Devlina Chakravarty Managing Director “The company has delivered a rob

19.9%

4 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Margin: 15.7% 19.9% 15.3% 19.6% Dr. Devlina Chakravarty Managing Director “The company has delivered a robust per

15.3%

Y25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Margin: 15.7% 19.9% 15.3% 19.6% Dr. Devlina Chakravarty Managing Director “The company has delivered a robust performanc

19.6%

FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Margin: 15.7% 19.9% 15.3% 19.6% Dr. Devlina Chakravarty Managing Director “The company has delivered a robust performance in Q3

“Devlina Chakravarty Managing Director “The company has delivered a robust performance in Q3 FY25 and 9M FY25, driven by our unwavering focus on improving key business metrics and operational efficiencies.”

“With this, we expect to further improve our performance by leveraging economies of scale and improving cost efficiencies.”

“We have also announced advanced tech-driven physiotherapy services in a strategic tie-up with Abhinav Bindra Targeting Performance (ABTP), aiming to revolutionise patient care by offering tailor made services.”

“Aligned with our strategic growth initiatives, we are streamlining our efforts to launch operations at our recently announced Raipur facility within the next year, marking our access into central India.”

“The strong growth in financial metrics has been driven by: • Leveraging economies of scale to improve operational efficiency through better allocation of fixed costs 1,459 1,378 1,036 1,059 665 12.6% 15.0% 18.0% 17.6% 21.2% 367 18.2% 498 464 • Plugging revenue leakages and running cost optimisation programs 22.3% 21.4% • Supply chain and energy efficiency optimisations FY22 FY23 FY24 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25”

“EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 17 Q3 and 9M FY25 Financial Performance (Consolidated) Particulars (INR Mn) Q3 FY25 Q3 FY24 Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisation expenses EBIT EBIT Margin Finance Cost PBT Total tax PAT PAT Margin”

Note

5

Margin

1

Margin

15.7% 19.9% 15.3% 19.6% Dr. Devlina Chakravarty Managing Director “The company has delivered a robust performance in Q3 FY25 and 9M FY25, driven by our unwavering focus on improving key business metrics and operational efficiencies. Despite this being a seasonally muted quarter, we have been able to achieve YoY growth and posted highest ever ARPOB by optimising the payer mix. Additionally, our increasing revenue contribution from international patients underscores our prominence as a preferred destination for Medical Value Travel. To cater to our growing customer base, we are focusing on ramping up the occupancy in the third tower. With this, we expect to further improve our performance by leveraging economies of scale and improving cost efficiencies. During the quarter, we have taken initiatives to enhance operational efficiencies by removing bottlenecks in the processes and improving patient experience. We have also announced advanced tech-driven physiotherapy services in a strategic

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 3 Accreditations and Centres of Excellence Accreditations Centres of Excellence National Accreditation Board for Hospitals & Healthcare Providers Artemis Organ Transplant Centre Artemis Women and Child Centre National Accreditation Board for Hospitals & Healthcare Providers - Blood Bank / Blood Centre National Accreditation Board for Hospitals & Healthcare Providers Certified Nursing Services Artemis Minimally Invasive & Bariatric Surgery Artemis Emergency & Trauma Centre Artemis Heart Centre Artemis Cancer Centre Intertek ISO 27001 Certificate First hospital in Gurugram to receive accreditation by Joint Commission International (JCI), USA The Laboratory services accredited by NABL based on ISO 15189:2012 for a specified scope of tests National Accreditation Board for Hospitals & Healthcare Providers – Ethics Committee Artemis Gastrosciences Centres Artemis Cosmetology & Plastic Surgery Centre Artemis

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 8 Artemis Hospital Gurgaon Q3 FY25 Revenue Segmentation by Speciality Q3 FY25 Revenue Segmentation by Payer 17% 20% 18% 2% 3% 2% 3% 3% 3% 7% 9% 14% 16% 19% 30% 33% Oncology Cardiology Nephrology Liver Transplant Neuro Internal Medicine Gastroentrology Obs & Gynae Orthopaedics General surgery Pulmonology Other Specialities International Patients Domestic Cash Patients Insured Patients Government Schemes 9 Artemis Hospital Gurgaon 9M FY25 Revenue Segmentation by Speciality 9M FY25 Revenue Segmentation by Payer 17% 19% 18% 2% 3% 3% 3% 3% 4% 16% 20% 28% 34% 6% 9% 15% Oncology Cardiology Nephrology Liver Transplant Neuro Internal Medicine Gastroentrology Obs & Gynae Orthopaedics General surgery Pulmonology Other Specialities International Patients Domestic Cash Patients Insured Patients Government Schemes 10 Artemis’ Ventures Overview Artemis Lite • Friendly neighborhood multi speciality hospitals, designed

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 17 Q3 and 9M FY25 Financial Performance (Consolidated) Particulars (INR Mn) Q3 FY25 Q3 FY24 Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisation expenses EBIT EBIT Margin Finance Cost PBT Total tax PAT PAT Margin

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 2,431 2,324 88 2,412 1,404 375 170 463 19.9% 115 348 15.0% 80 268 62 206 8.9% 2,287 2,188 18 2,206 1,341 347 173 344 15.7% 102 243 11.1% 80 163 48 116 5.3% YoY% 6.3% 6.2% 393.0% 9.3% 4.7% 8.0% -1.8% 34.4% 12.7% 43.5% 0.6% 64.4% 30.6% 78.3% Q2 FY25 QoQ% 9M FY25 9M FY24 2,523 2,414 74 2,489 1,449 359 184 497 20.6% 112 385 16.0% 80 306 84 221 9.2% -3.6% -3.7% 18.3% -3.1% -3.1% 4.5% -7.5% -6.9% 2.5% -9.7% 0.3% -12.3% -26.3% -6.9% 7,298 6,970 206 7,177 4,193 1,092 526 1,365 19.6% 334 1,031 14.8% 241 790 197 593 8.5% 6,865 6,533 55 6,588 4,062 1,029 495 1,002 15.3% 293 709 10.9% 227 482 134 348 5.3% YoY% 6.3% 6.7% 278.3% 8.9% 3.2% 6.2% 6.3% 36.3% 14.2% 45.4% 6.2% 63.9% 47.7% 70.1% 18 Q3 and 9M FY25 Financial Performance (Standalone) Particulars (INR Mn) Q3 FY25 Q3 FY24 Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 2,375 2,269 88 2,357 1,373 363 164 456 20.1% 109 347 15.3% 77 270 63 208 9.2% 2,197 2,103 17 2,120 1,299 334 153 334 15.9% 96 238 11.3% 76 163 48 115 5.5% YoY% 8.1% 7.9% 415.0% 11.2% 5.7% 8.9% 7.0% 36.6% 14.2% 45.6% 1.2% 66.3% 31.8% 80.4% Q2 FY25 QoQ% 9M FY25 9M FY24 2,454 2,347 75 2,422 1,410 347 172 493 21.0% 106 387 16.5% 76 311 85 226 9.6% -3.2% -3.3% 17.4% -2.7% -2.6% 4.7% -4.5% -7.4% 3.2% -10.3% 0.7% -13.0% -26.5% -7.9% 7,108 6,785 207 6,991 4,086 1,057 498 1,350 19.9% 318 1,032 15.2% 230 803 200 603 8.9% 6,603 6,284 54 6,338 3,917 988 456 977 15.5% 276 701 11.2% 215 486 134 352 5.6% YoY% 7.6% 8.0% 281.8% 10.3% 4.3% 7.0% 9.4% 38.2% 15.2% 47.2% 6.7% 65.2% 49.6% 71.1% 19 Disclosure This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Arte